Loading patent…
AssigneeJapan Science and Technology Agency
InventorsTsukasa Seya, Misako Matsumoto, Hiroyuki Oshiumi
Estimating the term…
A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or NO: 4, has the property of specifically binding to the mammalian Toll-like receptor 3 and a property of inducing type I interferon production. A mutant of the adaptor protein TICAM- 1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4. The gene is a gene encoding the adaptor protein TICAM-1.
A cell comprising a vector containing a gene encoding a protein made of an amino acid sequence set forth in SEQ ID NO:
A therapeutic agent for treating a disease that is able to be ameliorated by enhancing Type I interferon production, the therapeutic agent containing a protein made of an amino acid sequence set forth in SEQ ID NO:
A therapeutic agent for treating a disease that is able to be ameliorated by enhancing Type I interferon production, the therapeutic agent containing a vector containing a gene encoding a protein made of an amino acid sequence set forth in SEQ ID NO:
A therapeutic agent for treating a disease that is able to be ameliorated by enhancing Type I interferon production, the therapeutic agent containing a cell containing a vector containing a gene encoding a protein made of an amino acid sequence set forth in SEQ ID NO:
11-22. (canceled)
Dependencies are inferred from the claim text.